Galapagos’ GLPG-3970 move into next phase improves by nine points
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

LoA Update: Galapagos’ potential to move GLPG-3970 into next development phase improves by nine points with Phase II ulcerative colitis trial’s completion

By Manasi Vaidya 07 Jul 2021

Galapagos’ Phase II ulcerative colitis trial’s close drove the SIK2/SIK3 inhibitor GLPG-3970 Phase Transition Success Rate (PTSR) score to 38%, as of 2 July.

LoA Update: Galapagos’ potential to move GLPG-3970 into next development phase improves by nine points with Phase II ulcerative colitis trial’s completion
GLPG-3970 is the most advanced asset in the company’s Toledo programme focused on candidates that target salt-inducible kinases (SIK). Credits: StudioMolekuul/ Shutterstock.com.

Galapagos’ Phase II ulcerative colitis trial’s close drove the SIK2/SIK3 inhibitor GLPG-3970 Phase Transition Success Rate (PTSR) score to 38%, as of 2 July.

PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next. The Phase II trial’s (NCT04577794) status on ClinicalTrials.gov was changed to ‘completed’ on 30 June, which pushed the drug’s PTSR score up by 9 points. PTSR is one of the metrics used to calculate a drug’s Likelihood of Approval (LoA), which also sprung by three points to 13% following this trial’s completion.

GLPG-3970 is the most advanced asset in the company’s Toledo programme focused on candidates that target salt-inducible kinases (SIK). The SIK3 inhibitor GLPG-4399 is being studied in a Phase I trial (NCT04653467), while others are still in preclinical studies. The Phase II ulcerative colitis study is one of five proof-of-concept trials with GLPG-3970, which is designed to stimulate anti-inflammatory cytokines and inhibit pro-inflammatory cytokines. Other inflammatory disorders where GLPG-3970 is being studied include psoriasis, rheumatoid arthritis, systemic lupus erythematosus and primary Sjogren’s syndrome. As per its 1Q report, Galapagos intends to pursue further development plans in 2H based on results from these trials.

The LoA score, which is calculated by GlobalData’s analysis using a combination of machine learning and a proprietary algorithm, along with PTSR can be calculated for a drug by considering characteristics like Therapy Area, Indication and Molecule Type.

Manasi Vaidya is a Associate Editor for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.